Marshall Wace’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-28,367
| Closed | -$129K | – | 2914 |
|
|
2025
Q3 | $129K | Sell |
28,367
-21,261
| -43% | -$62.7K | ﹤0.01% | 2627 |
|
|
2025
Q2 | $107K | Buy |
+49,628
| New | +$139K | ﹤0.01% | 2533 |
|
|
2025
Q1 | – | Sell |
-98,027
| Closed | -$458K | – | 2587 |
|
|
2024
Q4 | $458K | Buy |
98,027
+55,130
| +129% | +$371K | ﹤0.01% | 2068 |
|
|
2024
Q3 | $301K | Sell |
42,897
-161,722
| -79% | -$1.17M | ﹤0.01% | 2142 |
|
|
2024
Q2 | $1.4M | Buy |
204,619
+70,768
| +53% | +$658K | ﹤0.01% | 1535 |
|
|
2024
Q1 | $1.89M | Buy |
+133,851
| New | +$2.04M | ﹤0.01% | 1393 |
|
|
2023
Q4 | – | Sell |
-23,733
| Closed | -$356K | – | 2123 |
|
|
2023
Q3 | $356K | Buy |
+23,733
| New | +$426K | ﹤0.01% | 1823 |
|
|
2023
Q1 | – | Sell |
-34,140
| Closed | -$198K | – | 2600 |
|
|
2022
Q4 | $198K | Sell |
34,140
-16,434
| -32% | -$125K | ﹤0.01% | 2704 |
|
|
2022
Q3 | $481K | Buy |
+50,574
| New | +$665K | ﹤0.01% | 2752 |
|
|
2022
Q1 | – | Sell |
-20,602
| Closed | -$364K | – | 3279 |
|
|
2021
Q4 | $364K | Buy |
+20,602
| New | +$412K | ﹤0.01% | 2955 |
|
|
2021
Q1 | – | Sell |
-35,817
| Closed | -$3.88M | – | 2421 |
|
|
2020
Q4 | $3.88M | Sell |
35,817
-1,155
| -3% | -$143K | 0.02% | 666 |
|
|
2020
Q3 | $3.81M | Buy |
+36,972
| New | +$5.54M | 0.02% | 606 |
|
|
2014
Q4 | – | Sell |
-4,541
| Closed | -$1.55M | – | 790 |
|
|
2014
Q3 | $1.55M | Buy |
+4,541
| New | +$1.35M | 0.02% | 487 |
|
Marshall Wace's ADVM Position: Q4 2025 in Review
Marshall Wace sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 28,367 shares — an estimated $129K sold.
Marshall Wace first reported a position in ADVM in Q3 2014 and held it in 13 quarters. The position peaked at $3.88M in Q4 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Marshall Wace reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Marshall Wace sold 28,367 Adverum Biotechnologies shares in Q4 2025, an estimated $129K.
- Marshall Wace first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 13 quarters.
- Marshall Wace's Adverum Biotechnologies position peaked at $3.88M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.